Opendata, web and dolomites

mP-CSE

Micro-physiological circadian platform for safety and efficacy assessment of drugs and cosmetics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mP-CSE project word cloud

Explore the words cloud of the mP-CSE project. It provides you a very rough idea of what is the project "mP-CSE" about.

limitations    hire    huge    costly    toxic       reduce    effect    rhythm    human    body    incorporation    dynamics    3d    brain    administration    liver    enhances    single    roi    tests    laboratory    organ    billion    turn    vascular    withdrawal    detect    platforms    functionally    food    risky    heart    function    latest    medicines    medications    69    mimic    pharmaceutical    smart    innovation    microphysiological    predicting    market    adjusting    ltd    ultimately    time    stress    70    helping    drugs    tested    technologies    humans    chips    platform    animals    alternative    tissue    maximum    rate    global    multiple    13    safe    2025    scaled    kidney    dose    circadian    chip    cagr    moc    animal    commercialization    companies    precise    patients    uses    rhythms    schemes       drug    organs    cosmetic    compounds    employees    proven    models    biotechnology    groundbreaking    sensing    treatment    5b    physiological    company    seeking    efficacy   

Project "mP-CSE" data sheet

The following table provides information about the project.

Coordinator
TISSUE DYNAMICS LTD 

Organization address
address: PARK HI-TECH, GIVAT RAM
city: JERUSALEM
postcode: 91904
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.tissuedynamics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TISSUE DYNAMICS LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Tissue Dynamics Ltd. is a groundbreaking biotechnology company focused on developing smart microphysiological platform technologies for drug, food, and cosmetic development. Pharmaceutical and cosmetic companies face huge costs of developing and testing new products (an average of €2.5B to develop a single drug), which is increasing over the years. Traditionally, these tests have been carried out in animal models whose limitations in predicting human responses are significant (70% of drugs toxic to humans are not toxic to animals). These limitations lead to the withdrawal of many drugs in the market, making drug development a costly risky process. Organ-on-chip platforms, developed in recent years, have proven to be a better alternative to current laboratory models, offering more physiological and similar characteristics to the human body. Tissue Dynamics goal is to provide a functionally scaled Multi Organ-on-Chip (MOC) platform that uses real-time sensing of tissue function to detect the effect of drug-induced physiological stress in multiple 3D vascular organs (liver, heart, brain, kidney). Our latest innovation has been the incorporation of factors that mimic circadian rhythms in the organs, which is essential to test the physiological impact of the compounds tested. On the other hand, the incorporation of the circadian rhythm in our chips enhances the development of treatment schemes, adjusting in a more precise way the dose and the time of administration of the medications, seeking the maximum efficacy of them. The global Organ-on-Chip market is a rapidly-growing, estimated to reach $6.13 Billion by 2025, with an expected growth rate of CAGR 69.4%. Our platform will reduce the cost of new drugs development ultimately, helping patients by making more safe and effective medicines reach the market. In turn we expect ROI of 5 after five years of commercialization and hire 10 new employees.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-CSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-CSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More